PharmaPoint: Atrial Fibrillation - Global Drug Forecast and Market Analysis to 2023
Atrial fibrillation (AF) is the most common cardiac arrhythmia and is a heart condition that causes an irregular and often abnormally fast heart rate. Various therapeutic options are available to treat patients with AF, and most patients will receive some form of antithrombotic therapy, a heart rate control agent, and potentially, an antiarrhythmic drug for rhythm control. All sectors of the AF market have historically been saturated with generics, with the vitamin K antagonists such as warfarin playing an important role in stroke prevention in AF. However, since 2010, and the launch of the first of the new oral anticoagulants (NOACs), a shift in the treatment of patients with AF has occurred. The NOACs offer a significant advancement in anticoagulation and their continued uptake will be the main driver of growth in the AF market over the next 10 years. In contrast, despite a great unmet need for safer antiarrhythmic drugs, developments in this field are expected to be much slower. Two potential antiarrhythmic drugs are in late-stage development and are forecast to enter the market within the next decade: Gilead’s ranolazine/dronedarone and ChanRx’s vanoxerine. Read Complete Report with TOC:http://www.marketresearchstore.com/report/pharmapoint-atrial-fibrillation-global-drug-forecast-and-13799#requestSample
Atrial fibrillation (AF) is the most common cardiac arrhythmia and is a heart condition that causes an irregular and often abnormally fast heart rate. Various therapeutic options are available to treat patients with AF, and most patients will receive some form of antithrombotic therapy, a heart rate control agent, and potentially, an antiarrhythmic drug for rhythm control.
All sectors of the AF market have historically been saturated with generics, with the vitamin K antagonists such as warfarin playing an important role in stroke prevention in AF. However, since 2010, and the launch of the first of the new oral anticoagulants (NOACs), a shift in the treatment of patients with AF has occurred. The NOACs offer a significant advancement in anticoagulation and their continued uptake will be the main driver of growth in the AF market over the next 10 years.
In contrast, despite a great unmet need for safer antiarrhythmic drugs, developments in this field are expected to be much slower. Two potential antiarrhythmic drugs are in late-stage development and are forecast to enter the market within the next decade: Gilead’s ranolazine/dronedarone and ChanRx’s vanoxerine.
Read Complete Report with TOC:http://www.marketresearchstore.com/report/pharmapoint-atrial-fibrillation-global-drug-forecast-and-13799#requestSample
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
<strong>Market</strong> Research S<strong>to</strong>re<br />
<strong>Atrial</strong> <strong>Fibrillation</strong> <strong>Global</strong><br />
<strong>Market</strong><br />
Size, Share, <strong>Global</strong> Trends,<br />
<strong>Analysis</strong>, Research Report<br />
<strong>and</strong> <strong>Forecast</strong>,<br />
2014-<strong>2023</strong><br />
www.marketresearchs<strong>to</strong>re.com<br />
sales@marketresearchs<strong>to</strong>re.com
Table of content<br />
Report Description<br />
<strong>Atrial</strong> fibrillation (AF) is the most common cardiac arrhythmia <strong>and</strong> is a heart<br />
condition that causes an irregular <strong>and</strong> often abnormally fast heart rate. Various<br />
therapeutic options are available <strong>to</strong> treat patients with AF, <strong>and</strong> most patients will<br />
receive some form of antithrombotic therapy, a heart rate control agent, <strong>and</strong><br />
potentially, an antiarrhythmic drug for rhythm control.<br />
All sec<strong>to</strong>rs of the AF market have his<strong>to</strong>rically been saturated with generics, with<br />
the vitamin K antagonists such as warfarin playing an important role in stroke<br />
prevention in AF. However, since 2010, <strong>and</strong> the launch of the first of the new oral<br />
anticoagulants (NOACs), a shift in the treatment of patients with AF has occurred.<br />
The NOACs offer a significant advancement in anticoagulation <strong>and</strong> their continued<br />
uptake will be the main driver of growth in the AF market over the next 10 years.<br />
In contrast, despite a great unmet need for safer antiarrhythmic drugs,<br />
developments in this field are expected <strong>to</strong> be much slower. Two potential<br />
antiarrhythmic drugs are in late-stage development <strong>and</strong> are forecast <strong>to</strong> enter the<br />
market within the next decade: Gilead’s ranolazine/dronedarone <strong>and</strong> ChanRx’s<br />
vanoxerine.
Visit Complete Report @<br />
http://www.marketresearchs<strong>to</strong>re.com/report/pharmapoint-atrial-fibrillationglobal-drug-forecast-<strong>and</strong>-13799<br />
Table of content<br />
Report Description<br />
Highlights<br />
Key Questions Answered<br />
- The anticoagulant market for stroke prevention in AF has become increasingly<br />
crowded. How will the drug treatment l<strong>and</strong>scape for AF change? Which of the<br />
NOACs will become the market leader over the next ten years? What are the key<br />
drivers <strong>and</strong> barriers <strong>to</strong> this change?<br />
- The AF market is marked by the presence of a number of unmet needs. What are<br />
the main unmet needs in the treatment of AF? Will the drugs under development<br />
fulfil the unmet needs of the AF market?<br />
- Will any of the late-stage antiarrhythmic drugs make a significant impact on<br />
the AF market? Which of these drugs will have the highest peak sales at the<br />
end of the forecast period, <strong>and</strong> why?
Table of content<br />
Report Description<br />
Key Findings<br />
- The major driver for the growth of the AF market will be the continued uptake of<br />
the NOACs for the prevention of stroke in patients with AF. Due <strong>to</strong> the advances<br />
that the NOACs provide in terms of improved safety <strong>and</strong> the lack of a need for<br />
routine moni<strong>to</strong>ring, NOAC uptake will continue <strong>to</strong> increase, taking market share<br />
away from vitamin K antagonists, such as warfarin.<br />
- The second major driver will be the approval <strong>and</strong> launch of the first antidotes for<br />
the NOACs, which will alleviate physician <strong>and</strong> patient concerns regarding a lack of<br />
a reversal agent in the event of uncontrolled bleeding, <strong>and</strong> will increase overall<br />
uptake.<br />
- Despite a great unmet need for safer antiarrhythmic drugs, developments in this<br />
field are expected <strong>to</strong> be much slower due <strong>to</strong> the high risk involved in developing<br />
these drugs. Barriers <strong>to</strong> growth include the requirement for large, costly, <strong>and</strong><br />
comprehensive clinical trials <strong>to</strong> support regula<strong>to</strong>ry approval of cardiovascular<br />
drugs, which will deter drug developers wanting <strong>to</strong> enter the AF market. Widely<br />
available generic antiarrhythmic drugs will also make it difficult for any novel<br />
rhythm control agents <strong>to</strong> gain reimbursement <strong>and</strong> wider uptake.
Table of content<br />
Report Description<br />
Scope<br />
- Overview of AF, including epidemiology, etiology, pathophysiology, symp<strong>to</strong>ms,<br />
diagnosis, <strong>and</strong> treatment guidelines.<br />
- Annualized AF therapeutics market revenue, annual cost of therapy, <strong>and</strong><br />
treatment usage pattern data from 2013, forecast for ten years <strong>to</strong> <strong>2023</strong>.<br />
- Key <strong>to</strong>pics covered include strategic competi<strong>to</strong>r assessment, market<br />
characterization, unmet needs, clinical trial mapping, <strong>and</strong> implications for the AF<br />
therapeutics market.<br />
- Pipeline analysis: comprehensive data split across different phases, emerging<br />
novel trends under development, <strong>and</strong> detailed analysis of late-stage pipeline<br />
drugs.<br />
- <strong>Analysis</strong> of the current <strong>and</strong> future market competition in the global AF<br />
therapeutics market. Insightful review of the key industry drivers, restraints, <strong>and</strong><br />
challenges. Each trend is independently researched <strong>to</strong> provide qualitative analysis<br />
of its implications.
Table of content<br />
Report Description<br />
Reasons <strong>to</strong> buy<br />
- Develop <strong>and</strong> design your in-licensing <strong>and</strong> out-licensing strategies through a<br />
review of pipeline products <strong>and</strong> technologies, <strong>and</strong> by identifying the companies<br />
with the most robust pipeline.<br />
- Additionally a list of acquisition targets included in the pipeline product company<br />
list.<br />
- Develop business strategies by underst<strong>and</strong>ing the trends shaping <strong>and</strong> driving the<br />
global AF therapeutics market.<br />
- Drive revenues by underst<strong>and</strong>ing the key trends, innovative products <strong>and</strong><br />
technologies, market segments, <strong>and</strong> companies likely <strong>to</strong> impact the global AF<br />
therapeutics market in the future.<br />
- Formulate effective sales <strong>and</strong> marketing strategies by underst<strong>and</strong>ing the
Table of content<br />
Report Description<br />
competitive l<strong>and</strong>scape <strong>and</strong> by analysing the performance of various competi<strong>to</strong>rs.<br />
- Identify emerging players with potentially strong product portfolios <strong>and</strong> create<br />
effective counter-strategies <strong>to</strong> gain a competitive advantage.<br />
- Track drug sales in the global AF therapeutics market from 2013-<strong>2023</strong>.<br />
- Organize your sales <strong>and</strong> marketing efforts by identifying the market categories<br />
<strong>and</strong> segments that present maximum opportunities for consolidations,<br />
investments <strong>and</strong> strategic partnerships.<br />
Request For Sample @<br />
http://www.marketresearchs<strong>to</strong>re.com/report/pharmapoint-atrial-fibrillationglobal-drug-forecast-<strong>and</strong>-13799#requestSample<br />
Browse Full Report with TOC @<br />
http://www.marketresearchs<strong>to</strong>re.com/report/pharmapoint-atrial-fibrillationglobal-drug-forecast-<strong>and</strong>-13799#reportTableOfContent
About Us<br />
<strong>Market</strong> Research S<strong>to</strong>re is a single destination for all the industry,<br />
company <strong>and</strong> country reports. We feature large reposi<strong>to</strong>ry of latest<br />
industry reports, leading <strong>and</strong> niche company profiles, <strong>and</strong> market<br />
statistics released by reputed private publishers <strong>and</strong> public<br />
organizations.<br />
Contact Us<br />
Stay With Us:<br />
TELEPHONE: +1-386-310-3803<br />
E-MAIL:<br />
sales@marketresearchs<strong>to</strong>re.com<br />
Suite #8138, 3422 SW<br />
15 Street,<br />
Deerfield Beach, Florida<br />
33442<br />
United States
Change language